caa a22 4500 465789897 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00198590 doi (NATIONALLICENCE)springer-10.1007/BF00198590 A semi-automated neutral red based chemosensitivity assay for drug screening [Elektronische Daten] [Paul Cavanaugh Jr., Patricia Moskwa, William Donish, Paula Pera, Debra Richardson, Angelo Andrese] Summary: A semi-automated colorometric chemosensitivity assay was developed. The assay utilizes the vital stain neutral red for the rapid screening of potential anticancer agents using solid tumor cell lines. The cell lines used in this assay and presented in this report are CX-1 colon adenocarcinoma and A549 lung carcinoma. The assay, performed in 96 well tissue culture plates, allows for short drug exposure times (3 hrs.) followed by quantitation of cell number (neutral red absorbance) following four cell doubling times. Cell number directly correlated with absorbance of eluted neutral red at 540 nm. However, optimal amounts of dye and staining times varied between cell lines. IC50 concentrations (for inhibition of cell growth) determined using this assay were in good agreement with results from clonogenic assays using similar drug treatment conditions. The assay technique was determined to be capable of detecting antineoplastic compounds operating by a wide variety of mechanisms. Kluwer Academic Publishers, 1990 anticancer nationallicence drug screening nationallicence neutral red nationallicence cell culture nationallicence chemosensitivity nationallicence Cavanaugh Jr. Paul Chemotherapeutics Research Laboratory, Eastman Kodak Company, 14650, Rochester, New York, USA aut Moskwa Patricia Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut Donish William Life Sciences Research Laboratories, Eastman Kodak Company, 14650, Rochester, New York, USA aut Pera Paula Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut Richardson Debra Life Sciences Research Laboratories, Eastman Kodak Company, 14650, Rochester, New York, USA aut Andrese Angelo Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 347-354 0167-6997 8:4<347 1990 8 10637 https://doi.org/10.1007/BF00198590 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00198590 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Cavanaugh Jr Paul Chemotherapeutics Research Laboratory, Eastman Kodak Company, 14650, Rochester, New York, USA aut NATIONALLICENCE 700 1- Moskwa Patricia Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut NATIONALLICENCE 700 1- Donish William Life Sciences Research Laboratories, Eastman Kodak Company, 14650, Rochester, New York, USA aut NATIONALLICENCE 700 1- Pera Paula Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut NATIONALLICENCE 700 1- Richardson Debra Life Sciences Research Laboratories, Eastman Kodak Company, 14650, Rochester, New York, USA aut NATIONALLICENCE 700 1- Andrese Angelo Sterling Research Group, Sterling Drug Inc., 19355, Malvern, PA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 347-354 0167-6997 8:4<347 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer